News from Pancreatic Cancer Oral Sessions

Abstract LBA4002 Oral Abstract Session, Mon, 3:00 PM-6:00 PM

Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. First Author: Geertjan Van Tienhoven, Department of Radiation Oncology, Academic Medical Center, Amsterdam, Netherlands

Conclusion: Our preliminary data show that preoperative chemoradiotherapy significantly improves outcome in (borderline) resectable pancreatic cancer compared to immediate surgery. Updated results will be presented at the meeting. Clinical trial information: NTR3709.

 

Abstract LBA4001 Oral Abstract Session, Mon, 3:00 PM-6:00 PM

Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. First Author: Thierry Conroy, Institut de Cance ́rologie de Lorraine, Vandoeuvre- Les-Nancy, France

Conclusion: Adjuvant mFOLFIRINOX is safe and significantly improves DFS, MFS and OS compared to gem. Clinical trial information: NCT01526135

 

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35- PANOPTIMOX). First Author: Laetitia Dahan, La Timone University Hospital, Marseille, France

 

Conclusions: Maintenance with LV5FU2 appears to be feasible and effective in patients with mPC controlled after 4m of induction chemotherapy with FOLFIRINOX. Severe neurotoxicity rate was higher in the maintenance therapy arm, likely because of higher cumulative oxaliplatin dose.1Conroy NEJM 2011.Clinical trial information: NCT02352337